All relevant data are within the paper and its Supporting Information files.

Introduction {#sec005}
============

Inflammatory bowel disease (IBD), which mainly consists of ulcerative colitis (UC) and Crohn\'s disease (CD), is a group of chronic non-specific gastrointestinal inflammatory conditions. IncreasedIBD incidence and prevalence havebeen observed in different regions of the world\[[@pone.0126803.ref001]\]. IBD is an autoimmune disease that results from an aberrant immune response to intestinal bacteria or other foreign substances as well as genetic factors\[[@pone.0126803.ref002]\]. Previous studies have demonstrated that genetic polymorphisms contribute to individual variations in the genetic susceptibility to IBD\[[@pone.0126803.ref003]\]. Among the genetically predisposing alleles tightly linked to IBD, Toll-like receptor (TLR) polymorphisms have attracted increasing attention in recent years\[[@pone.0126803.ref004]\].

Toll-like receptors (TLRs) are transmembrane proteins usually expressed by antigen presenting cells; they are important immune receptors that participate in the recognition of pathogen-associated molecular patterns and activation of signal transduction pathways of antimicrobial genes, by identifying and binding to small molecular components on pathogens\[[@pone.0126803.ref005]\]. TLRs also play an important role in the digestive system. In addition, they can recognize invading microbes in the intestinal barrier and activate the immune response. However, sustained hyper-activation of TLRs may lead to chronic inflammation in IBD. At present, at least 13 TLR family members recognizing different pathogens independently or together in various internal organs have been described, of which TLR2 and TLR4 are most commonly studied for their association with risk of IBD\[[@pone.0126803.ref006]\].

TLR2, located at 4q31.3, recognizes bacterial lipopeptides and lipoteichoic acid found abundantly in the cell wall of Gram positive bacteria\[[@pone.0126803.ref007]\]. TLR4, located at 9q33.1, serves as a surface receptor for lipopolysaccharides (LPS), the main endotoxins derived from Gram-negative bacteria\[[@pone.0126803.ref008]\]. In the normal intestine, TLR2 and TLR4 are expressed at low levels in intestinal epithelial cells (IECs), thus minimizing the recognition of luminal bacteria\[[@pone.0126803.ref009]\]. However, TLR2 and TLR4 are up-regulated in primary IECs throughout the lower gastrointestinal tract in IBD patients, which may cause excessive immune response\[[@pone.0126803.ref010]--[@pone.0126803.ref012]\].

Population-based case-control show an association between TLR4 polymorphism and susceptibility to CD and UC. The association between TLR2 gene variantss and extensive colonic disease in UC and CD has also been discribed\[[@pone.0126803.ref013]\]. TLR2 Arg677Trp (R677W, rs12191786) and Arg753Gln (R753Q, rs5743708), and TLR4 Asp299Gly (D299G, rs4986790) and Thr399Ile (T399I, rs4986791) polymorphisms are the most widely discussed SNPs in the investigation of the association between polymorphisms of TLR family and susceptibility to IBD. The association between TLR4 Asp299Gly and Thr399Ile polymorphisms and IBD is controversial. TLR2 single studies did not found the association of TLR2 Arg677Trp and Arg753Gln polymorphisms and IBD. However, these studies has relatively sample size and might be underpowered to reveal a small effect of the polymorphisms of TLR2 on IBD susceptibility. Meta-analysis can combine results from different studies to produce an estimate of the major effect with enhanced precision.The aim of this meta-analysis was to investigate the associations between TLR2 (Arg677Trp, Arg753Gln) and TLR4 (Asp299Gly, Thr399Ile) genetic polymorphisms and susceptibility to IBD.

Methods {#sec006}
=======

Literature search {#sec007}
-----------------

A systemic search was conducted on PubMed, Embase, Biosis Preview and China National Knowledge Infrastructure databases up to August 31, 2014 using the following keywords: (1) "toll-like receptor" or "TLR"; (2) "Crohn's disease" or "CD" or "ulcerative colitis" or "UC" or "inflammatory bowel disease" or "IBD"; (3) "polymorphism" or "variant" or "genotype". There was no language restriction and species were limited to human. References in the reviews and retrieved articles were hand-searched as well. For articles by the same author using the same case series, the study with the largest sample size was selected.

Inclusion criteria {#sec008}
------------------

The inclusion criteria were: (1) case-control study; (2) investigation evaluating the relationship between TLR2 (Arg677Trp, Arg753Gln) and TLR4 (Asp299Gly, Thr399Ile) genetic polymorphisms and IBD (CD or UC) susceptibility; (3) sufficient available published data for odds ratio (OR) estimation with 95% confidence interval (CI); (4) human study; (5) data not republished.

Data extraction and quality assessment {#sec009}
--------------------------------------

Missing data were requested by contacting study authors through email. Data were blindly extracted from all selected publications by two investigators (Cheng and Zhu) separately. For each of the included articles, the first author name, publication year, study population (ethnicity), source of controls, total numbers of patients and controls, and polymorphism frequencies in patients and controls were extracted. For studies that included subjects of different ethnic groups, data were extracted for each one. Any disagreement on a given item of the extracted data was fully discussed to reach a consensus.

Predefined criteria ([Table 1](#pone.0126803.t001){ref-type="table"}) based on the scale of Thakkinstian\[[@pone.0126803.ref014]\] were used to assess the methodological quality of eligible studies. The revised criteria cover the representativeness of cases and controls, assessment of IBD, genotyping examination, Hardy-Weinberg equilibrium (HWE) in the control population, and association assessment. Scores ranged from 0 (lowest) to 11 (highest). Articles with scores of less than 6 were considered to be low-quality studies, whereas those with scores equal to or higher than 6 were considered high-quality reports. Quality assessment was also performed by two authors separately (Yang and Yun). Disagreements were resolved by consensus as well.

10.1371/journal.pone.0126803.t001

###### Scale for methodologic Quality Assessment of the Single Nucleotide Polymorphism association studies of IBD.

![](pone.0126803.t001){#pone.0126803.t001g}

      Criteria                                                                                                                                       Score
  --- ---------------------------------------------------------------------------------------------------------------------------------------------- -------
  A   **Representativeness of cases**                                                                                                                
          Consecutive/randomly selected from case population with clearly defined sampling frame                                                     2
          Consecutive/randomly selected from case population without clearly defined sampling frame or with extensive inclusion/exclusion criteria   1
          No method of selection described                                                                                                           0
  B   **Representativeness of controls**                                                                                                             
          Controls were consecutive/randomly drawn from the same sampling frame (ward/community) as cases                                            2
          Controls were consecutive/randomly drawn from a different sampling frame as cases                                                          1
          Not described                                                                                                                              0
  C   **Ascertainment of IBD**                                                                                                                       
          Clearly described objective criteria for diagnosis of IBD                                                                                  2
          Diagnosis of IBD by patient self-report or by patient history                                                                              1
          Not described                                                                                                                              0
  D   **Genotyping examination**                                                                                                                     
          Genotyping done under "blinded" condition                                                                                                  1
          Unblinded or not mentioned                                                                                                                 0
  E   **Hardy-Weinberg equilibrium**                                                                                                                 
          Hardy-Weinberg equilibrium in control group                                                                                                2
          Hardy-Weinberg disequilibrium in control group                                                                                             1
          No checking for Hardy-Weinberg equilibrium                                                                                                 0
  F   **Association assessment**                                                                                                                     
          Assess association between genotypes and IBD with appropriate statistics and adjustment for confounders                                    2
          Assess association between genotypes and IBD with appropriate statistics without adjustment for confounders                                1
          Inappropriate statistics used                                                                                                              0

Statistical analysis {#sec010}
--------------------

Pooled crude odds ratios (ORs) and 95% confidence intervals (95% CIs) were determined to assess the associations between TLR2 (Arg677Trp, Arg753Gln) and TLR4 (Asp299Gly, Thr399Ile) genetic polymorphisms and the risk of IBD under dominant, recessive, additive and allele models, based on the extracted data. The fixed-effects (random-effects) model was used depending on the heterogeneity among studies\[[@pone.0126803.ref015], [@pone.0126803.ref016]\]. Subgroup analysis was performed to assess the ethnic-specific effects. Potential heterogeneity was examined by the chi-square based Q-test and I^2^. A P value for heterogeneity \< 0.10 or I^2^ \> 50% was considered statistically significant. Sensitivity analysis was performed by sequentially excluding each single study to assess the stability of the results\[[@pone.0126803.ref017]\]. Galbraith plots were performed to identify possible distinct articles, which might contribute to the heterogeneity\[[@pone.0126803.ref018]\]. Hardy-Weinberg equilibrium (HWE) in the control group was assessed by the chi-square test\[[@pone.0126803.ref019]\]. Potential publication bias was estimated by the funnel plot of the ORs versus their standard errors\[[@pone.0126803.ref020]\]. Funnel plot asymmetry was assessed by the Egger's test (linear regression test) when the number of studies included was more than 10. P value \> 0.10 indicated no significant publication bias\[[@pone.0126803.ref021]\]. Studies with P value \<0.1 were corrected using the Duval's trim and fill method\[[@pone.0126803.ref022]\]. All statistical analyses were performed with STATA 10.0 (StataCorp LP, College Station, TX).

Results {#sec011}
=======

Literature search {#sec012}
-----------------

This meta-analysis was performed and reported according to the PRISMA guidelines. The search of PubMed, Biosis Previews, Embase and two Chinese databases (Chinese National Knowledge Infrastructure and Wanfang databases) for relevant articles published up to July 2014 yielded 597 articles. A total of 36 articles\[[@pone.0126803.ref023]--[@pone.0126803.ref058]\]\[[@pone.0126803.ref023]--[@pone.0126803.ref058]\] met the inclusion criteria and were selected. Three article contained 2 separated studies each, as each of them involved two different populations. Overall, 39 studies, assessing 10970 cases and 7061 controls were included in the analysis. A flow chart demonstrating the selection process of relevant studies is represented in [Fig 1](#pone.0126803.g001){ref-type="fig"}.

![Flow chart showing literature search for studies of TLR2 and TLR4 polymorphism in relation to risk of CD and UC.](pone.0126803.g001){#pone.0126803.g001}

Study characteristics and quality assessment {#sec013}
--------------------------------------------

The basic information for each study, including authors and publication years, ethnicity, numbers of cases and controls, frequencies of various genotypes in IBD patients and healthy controls, and Hardy-Weinberg equilibrium (HWE) in healthy controls, are summarized in [Table 2](#pone.0126803.t002){ref-type="table"}. Of the 39 qualifying studies, 23 were conducted among Caucasian populations, 10carried out among Asians and 6 performed in other ethnicities. All studies were published between 2002 and 2013, and were case-control designed. IBD patients and controls were age and gender matched in 6 studies, while the other 33 studies did not specifically mention this detail in their reports. Allelic distribution for TLR2 and TLR4 is shown in [S1 Table](#pone.0126803.s002){ref-type="supplementary-material"}.

10.1371/journal.pone.0126803.t002

###### Characteristics of the included studies on TLR polymorphism and susceptibility of CD and UC.
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       Year of   Author                                     Region            TLR        Phenotype   Cases     Controls         HWE in                                            
  ---- --------- ------------------------------------------ ----------------- ---------- ----------- --------- ---------------- ----------------- ----- ------ ------------------ --------------------
  1    2002      Okayama\[[@pone.0126803.ref023]\]          Japanese          TLR4 299   UC          UC: 86    nr               nr                107   nr     nr                 equilibrium
  2    2004      Arnott\[[@pone.0126803.ref024]\]           Scotland          TLR4 299   CD&UC       CD: 234   43.7             28(21--41)        189   52.2   38(27--50)         equilibrium
                                                                                                     UC: 246   53.4             33(25--49)                                        equilibrium
  3    2004      Franchimont(1)\[[@pone.0126803.ref025]\]   Belgium           TLR4 299   CDs&UC      CD: 334   40.7             26.6±10.3         139   nr     nr                 equilibrium
                                                                                                     UC: 163   52.2             29.78±12.8                                        
  4    2004      Franchimont(2)\[[@pone.0126803.ref025]\]   Belgium           TLR4 299   CD          CD: 114   56.2             28.9±12.4         139   nr     nr                 equilibrium
  5    2004      Torok\[[@pone.0126803.ref026]\]            Germany           TLR4 299   CD&UC       CD: 102   36.3             40.9±13.7         145   49     44.6±12.5          equilibrium
                                                                              TLR4 399               UC: 98    45.9             42.7±13.3                                         
  6    2005      Brand \[[@pone.0126803.ref027]\]           Germany           TLR4 299   CD          CD: 204   47.1             37.8±11.8         199   49.8   46.4±15.3          equilibrium
                                                                              TLR4 399                                                                                            
  7    2005      Fries\[[@pone.0126803.ref028]\]            Italy             TLR4 299   CD          CD:23     56.5             43(15--75)        59    47.5   38(18--68)         nr/ equilibrium
  8    2005      Gazouli\[[@pone.0126803.ref029]\]          Greek             TLR4 299   CD&UC       CD: 120   nr               nr                100   nr     nr                 nr/disequilibrium
                                                                              TLR4 399               UC: 85    nr               nr                                                
  9    2005      Ouburg\[[@pone.0126803.ref030]\]           The Netherlands   TLR4 299   CD          CD:112    nr               nr                170   nr     nr                 nr/equilibrium
  10   2005      Braat\[[@pone.0126803.ref031]\]            The Netherlands   TLR4 299   CD&UC       CD: 441   35%              mean 40.7         137   nr     nr                 equilibrium
                                                                                                     UC: 226   53%              mean 44.4                                         
  11   2005      Oostenbrug\[[@pone.0126803.ref032]\]       The Netherlands   TLR4 299   CD&UC       CD: 393   nr               nr                296   nr     nr                 equilibrium
                                                                              TLR4 399               UC: 179   nr               nr                                                
  12   2005      Lakatos\[[@pone.0126803.ref033]\]          Hungary           TLR4 299   CD          CD:527    50.3             37.1±7.6          200   0.51   38.05±10.7         nr/ equilibrium
  13   2006      Figueroa\[[@pone.0126803.ref034]\]         Chile             TLR4 299   CD&UC       CD: 22    36.4             46.8(16--65)      20    nr     nr                 nr/imponderable
                                                                                                     UC: 22    40.9             37.8(19--67)                                      
  14   2006      Pierik\[[@pone.0126803.ref035]\]           Belgium           TLR2 753   CD&UC       CD:179    41.1             25.0±10.1         191   nr     nr                 equilibrium
                                                                              TLR4 299               UC:106    54.3             28.9±13.3                                         
  15   2007      Xiong\[[@pone.0126803.ref036]\]            China             TLR2 677   IBD         120       nr               nr                110   nr     nr                 nr/imponderable
                                                                              TLR2 753                                                                                            
                                                                              TLR4 299                                                                                            
                                                                              TLR4 399                                                                                            
  16   2007      Jiang\[[@pone.0126803.ref037]\]            China             TLR4 299   UC          UC:68     57.4             37.58±12.37       152   57.9   46.90±12.73        equilibrium
  17   2007      Xue\[[@pone.0126803.ref038]\]              China             TLR2 677   CD&UC       CD: 41    60.7             34\. 54±14. 21    135   55.6   41\. 85±10. 82     nr/imponderable
                                                                              TLR2 753               UC: 43    45\. 95±17. 11                                                     
                                                                              TLR4 299                                                                                            
                                                                              TLR4 399                                                                                            
  18   2007      Henckaerts\[[@pone.0126803.ref039]\]       Belgium           TLR2 753   CD&UC       CD: 874   41               24 (18--31)       312   45     39(30--57)         equilibrium
                                                                              TLR4 299               UC: 259   52               26 (21--36)                                       
  19   2007      Hong\[[@pone.0126803.ref040]\]             New Zealand       TLR2 753   CD          CD:182    nr               nr                188   nr     nr                 equilibrium
                                                                              TLR4 299                                                                                            
                                                                              TLR4 399                                                                                            
  20   2007      Baumgart(1)\[[@pone.0126803.ref041]\]      Hungary           TLR4 299   CD&UC       CD: 144   43.1             24±11.2           202   46.5   (18--54)           nr/ equilibrium
                                                                                                     UC: 118   37.3             31±10.6                                           
  21   2007      Baumgart(2)\[[@pone.0126803.ref041]\]      Germany           TLR4 299   CD&UC       CD: 235   38.3             26±10.3           403   42.4   (21--61)           nr/ equilibrium
                                                                                                     UC: 145   46.2             31±13.6                                           
  22   2007      Browning\[[@pone.0126803.ref042]\]         New Zealand       TLR4 299   CD&UC       CD: 389   36               nr                416   44     nr                 equilibrium
                                                                              TLR4 399               UC: 405   47               nr                                                
  23   2008      Rigoli\[[@pone.0126803.ref043]\]           Italy             TLR4 299   CD&UC       CD:133    52.6             43.5 ± 10.7       103   66     46.6 ± 9.8         equilibrium
                                                                              TLR4 399               UC:45     60               43.2 ± 11.0                                       
  24   2008      Hume\[[@pone.0126803.ref044]\]             Australia         TLR4 299   CD&UC       CD:619    nr               nr                360   nr     nr                 equilibrium
                                                                                                     UC:300    nr               nr                                                
  25   2008      Akin\[[@pone.0126803.ref045]\]             Turkey            TLR4 299   CD&UC       CD:108    nr               nr                191   52.4   35.2 ±11.2         nr/ equilibrium
                                                                              TLR4 399               UC:120    nr               nr                                                
  26   2008      Lappalainen\[[@pone.0126803.ref046]\]      Finland           TLR4 299   CD&UC       CD: 240   nr               nr                190   nr     nr                 equilibrium
                                                                              TLR4 399               UC: 459   nr               nr                                                
  27   2009      Ye\[[@pone.0126803.ref047]\]               Korea             TLR4 299   CD          CD: 380   62.6             27.2±7.7          380   52.3   36.6±13.8          nr/ disequilibrium
  28   2009      Zouiten-Mekki\[[@pone.0126803.ref048]\]    Tunisia           TLR4 299   CD&UC       CD:90     nr               nr                80    nr     nr                 nr/ disequilibrium
                                                                              TLR4 399               UC:30     nr               nr                                                
  29   2009      Queiroz\[[@pone.0126803.ref049]\]          Brazil            TLR2 677   CD&UC       CD:43     46.51            40.88±14.16       541   75.6   33.87±9.96         equilibrium
                                                                              TLR2 753               UC:42     14.29            38.93±14.73                                       
                                                                              TLR4 299                                                                                            
  30   2009      Bueno\[[@pone.0126803.ref050]\]            Belgium           TLR4 299   CD&UC       CD: 80    60               22.86±7.4         79    nr     nr                 equilibrium
                                                                                                     UC: 15    58.8             18.3±5.3                                          
  31   2010      Wagner\[[@pone.0126803.ref051]\]           Australia         TLR4 299   CD          CD: 72    63.9             11.6(2.2--17.2)   98    45.9   11.9 (1.7--19.8)   equilibrium
  32   2010      Shen\[[@pone.0126803.ref052]\]             China             TLR2 677   CD&UC       CD:30     60               32.5(14--64)      120                             equilibrium
                                                                              TLR2 753               UC:83     60.2             46.0(19--72)                                      
                                                                              TLR4 299                                                                                            
                                                                              TLR4 399                                                                                            
  33   2011      Chen(1)\[[@pone.0126803.ref053]\]          China             TLR2 677   CD&UC       CD:30     nr               nr                60    49     36.8 ± 12.2        equilibrium
                                                                              TLR2 753               UC:40     nr               nr                                                
                                                                              TLR4 299                                                                                            
  34   2011      Chen(2)\[[@pone.0126803.ref053]\]          China             TLR2 677   CD&UC       CD:30     nr               nr                84    48.5   33.2 ± 12.0        equilibrium
                                                                              TLR2 753               UC:46     nr               nr                                                
                                                                              TLR4 399                                                                                            
  35   2012      Sivaram\[[@pone.0126803.ref054]\]          India             TLR4 299   UC          UC: 139   nr               nr                176   nr     nr                 nr/ equilibrium
  36   2012      Azzam\[[@pone.0126803.ref055]\]            Saudi             TLR4399    CD          CD:46     67.4             30.43 ± 10.20     50    nr     nr                 nr/ equilibrium
  37   2012      Kim\[[@pone.0126803.ref056]\]              Korea             TLR2 677   CD&UC       CD: 45    56               32.1±11.4         178   49     47.2±13.0          equilibrium
                                                                              TLR2 753                                                                                            
                                                                              TLR4 299               UC: 99    46               49.8±14.7                                         
                                                                              TLR4 399                                                                                            
  38   2012      Guagnozzi\[[@pone.0126803.ref057]\]        Italia            TLR4 299   CD&UC       CD: 84    nr               nr                227   nr     nr                 nr/ equilibrium
                                                                                                     UC: 133   nr               nr                                                
  39   2013      Manolakis\[[@pone.0126803.ref058]\]        Greece            TLR4 299   CD&UC       CD: 187   47.8             43.23±22.9        274   55.2   46.9±22.4          equilibrium
                                                                              TLR4 399               UC: 163   63.1             50.1±18.6                                         

Of the 39 studies, 7 assessed the TLR2 Arg677Trp polymorphism, 10 studied the TLR2 Arg753Gln polymorphism, 37 evaluated the TLR4 Asp299Gly polymorphism and 17 studied the TLR4Thr399Ile polymorphism. There were 30 high quality and 9 low quality studies, respectively according to the set quality criteria ([Table 3](#pone.0126803.t003){ref-type="table"}). All low quality studies encompassed TLR4 polymorphism analyses.

10.1371/journal.pone.0126803.t003

###### Quality assessment of studies included.
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       Year of   Aurthor          Representativeness   Representativeness   Ascertainment   Genotyping   Hardy-Weinberg   Association   Total
  ---- --------- ---------------- -------------------- -------------------- --------------- ------------ ---------------- ------------- -------
  1    2002      Okayama          0                    0                    0               0            2                1             3
  2    2004      Torok            0                    0                    2               0            2                1             5
  3    2004      Arnott           2                    0                    2               0            2                1             7
  4    2004      Franchimont(1)   2                    2                    2               0            2                1             7
  5    2004      Franchimont(2)   2                    2                    2               0            2                1             7
  6    2005      Brand            0                    0                    2               0            2                1             5
  7    2005      Fries            2                    2                    1               0            0                1             6
  8    2005      Gazouli          2                    2                    2               0            0                1             7
  9    2005      Ouburg           2                    2                    2               0            0                1             7
  10   2005      Braat            2                    2                    2               0            2                1             9
  11   2005      Oostenbrug       2                    2                    2               0            2                1             9
  12   2005      Lakatos          2                    0                    2               0            0                1             5
  13   2006      Figueroa         2                    2                    2               0            0                1             7
  14   2006      Pierik           2                    2                    1               0            2                0             7
  15   2007      Xiong            2                    2                    2               0            0                1             7
  16   2007      Jiang            2                    2                    2               0            2                1             9
  17   2007      Xue              2                    2                    2               0            2                1             9
  18   2007      Henckaerts       2                    2                    2               0            2                0             8
  19   2007      Hong             1                    1                    2               0            2                1             7
  20   2007      Baumgart(1)      1                    1                    2               0            0                1             5
  21   2007      Baumgart(2)      1                    1                    2               0            0                1             5
  22   2008      Lappalainen      1                    1                    2               0            2                1             7
  23   2007      Browning         2                    1                    2               0            2                1             8
  24   2008      Rigoli           2                    2                    2               0            2                1             9
  25   2008      Hume             2                    1                    2               0            2                1             8
  26   2008      Akin             2                    2                    1               0            0                1             6
  27   2009      Ye               2                    2                    2               0            0                1             7
  28   2009      Zouiten-Mekki    0                    0                    2               0            0                1             3
  29   2009      Queiroz          2                    2                    2               0            2                2             8
  30   2009      Bueno            2                    2                    2               0            2                1             9
  31   2010      Wagner           2                    1                    2               0            2                1             8
  32   2010      Shen             2                    2                    2               0            2                1             9
  33   2011      Chen(1)          2                    2                    2               0            2                1             9
  34   2011      Chen(2)          2                    2                    2               0            2                1             9
  35   2012      Sivaram          0                    0                    2               0            0                1             3
  36   2012      Azzam            2                    2                    2               0            0                1             7
  37   2012      Kim              2                    2                    2               0            2                1             9
  38   2012      Guagnozzi        0                    0                    1               0            0                1             2
  39   2013      Manolakis        2                    1                    2               0            2                1             8

Main meta-analysis results {#sec014}
--------------------------

An estimation of the association between TLR2 Arg677Trp, Arg753Gln and TLR4Asp299Gly, Thr399Ile polymorphisms and susceptibility to CD and UC is presented in [Table 4](#pone.0126803.t004){ref-type="table"}. The corresponding forest plots are shown in [Fig 2](#pone.0126803.g002){ref-type="fig"}.

![Forest plot showing the association between TLR2 and TLR4 polymorphisms and CD and UC risk.\
Squares represent the effect size for the odds ratios of CD or UC risk among subjects. Error bars represent 95% confidence intervals (CI). Diamonds represent pooled estimates within each analysis. (a) TLR2 polymorphisms and CD/UC in dominant model; (b) TLR4 polymorphisms and CD/UC in dominant model.](pone.0126803.g002){#pone.0126803.g002}

10.1371/journal.pone.0126803.t004

###### Results of the meta-analysis of the relationship of TLR2 and TLR4 polymorphism with CD or UC risk.
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  Study                      Genetic model     OR     95% CI        I2(%)   P value   No. of study   Egger
  -------------------------- ----------------- ------ ------------- ------- --------- -------------- -------
  TLR2 677 vs CD             dominant model    3.54   0.71--17.71   0.00    0.99      6              /
                             additive model    3.54   0.71--17.71   0.00    0.99      6              /
                             recessive model   3.54   0.71--17.71   0.00    0.99      6              /
  TLR2 677 vs UC             dominant model    1.93   0.39--9.59    0.00    1.00      6              /
                             additive model    1.93   0.39--9.59    0.00    1.00      6              /
                             recessive model   1.93   0.39--9.59    0.00    1.00      6              /
  TLR2 753 vs CD             dominant model    0.84   0.53--1.33    0.00    0.84      9              /
                             allele model      2.69   0.77--9.44    0.00    1.00      9              /
  TLR2 753 vs UC             dominant model    1.14   0.63--2.05    0.00    1.00      8              /
                             allele model      1.14   0.63--2.05    0.00    1.00      8              /
  TLR4 299 vs CD             dominant model    1.44   1.27--1.63    20.50   0.15      33             0.50
                             additive model    1.62   0.98--2.67    0.00    1.00      32             0.39
                             recessive model   1.82   1.11--3.01    0.00    1.00      32             0.74
                             allele model      1.40   1.24--1.57    25.00   0.10      33             0.49
  TLR4 299 vs UC             dominant model    1.50   1.28--1.76    44.90   0.01      26             0.82
                             additive model    2.37   1.29--4.35    0.00    1.00      26             0.97
                             recessive model   2.25   1.22--4.12    0.00    1.00      26             0.91
                             allele model      1.40   1.22--1.62    43.60   0.01      27             0.62
  TLR4 399 vs CD             dominant model    1.26   1.03--1.54    0.00    0.97      16             0.04
                             additive model    1.45   0.66--3.18    0.00    0.98      16             0.59
                             recessive model   1.35   0.62--2.95    0.00    0.98      16             0.41
                             allele model      1.21   1.01--1.44    0.00    0.95      17             0.10
  TLR4 399 vs UC             dominant model    1.41   1.09--1.82    0.00    0.61      13             0.56
                             additive model    1.89   0.70--5.13    0.00    1.00      13             0.74
                             recessive model   1.84   0.68--5.00    0.00    1.00      13             0.65
                             allele model      1.26   1.02--1.56    0.00    0.52      14             0.36
  **High quality studies**                                                                           
  TLR4 299 vs CD             dominant model    1.56   1.35--1.80    3.00    0.42      26             0.47
                             additive model    1.72   0.98--3.02    0.00    1.00      25             0.44
                             recessive         1.94   1.10--3.40    0.00    1.00      25             0.60
                             allele model      1.50   1.31--1.72    12.20   0.29      26             0.47
  TLR4 299 vs UC             dominant model    1.55   1.28--1.87    49.10   0.01      20             0.66
                             additive model    2.49   1.25--4.95    0.00    0.99      20             0.97
                             recessive         2.35   1.18--4.67    0.00    0.99      20             0.88
                             allele model      1.51   1.16--1.98    47.10   0.01      21             0.46
  TLR4 399 vs CD             dominant model    1.16   0.92--1.46    0.00    0.98      13             0.03
                             additive model    1.50   0.65--3.46    0.00    0.92      13             0.53
                             recessive         1.40   0.61--3.21    0.00    0.92      13             0.37
                             allele model      1.13   0.93--1.37    0.00    0.96      14             0.14
  TLR4 399 vs UC             dominant model    1.32   1.00--1.75    0.00    0.78      11             0.38
                             additive model    1.65   0.55--4.90    0.00    1.00      11             0.43
                             recessive         1.62   0.54--4.81    0.00    1.00      11             0.41
                             allele model      1.19   0.95--1.49    0.00    0.76      12             0.24
  **Group by ethinicity**                                                                            
  TLR2 753 vs CD                                                                                     
  Asia                       dominant model    3.54   0.71--17.71   0.00    0.99      6              /
                             allele model      3.54   0.71--17.71   0.00    0.99      6              /
  Caucasian                  dominant model    0.73   0.36--1.47    0.00    0.48      2              /
                             allele model      1.05   0.07--16.82   0.00    0.99      2              /
  TLR2 753 vs UC                                                                                     
  Asian                      dominant model    1.93   0.39--9.59    0.00    1.00      6              /
                             allele model      1.93   0.39--9.59    0.00    1.00      6              /
  Caucasian                  dominant model    1.05   0.56--1.97    0.00    0.77      2              /
                             allele model      1.50   0.09--24.07   0.00    0.87      2              /
  TLR4 299 vs CD                                                                                     
  Asian                      dominant model    2.17   0.52--9.14    0.00    0.92      7              /
                             additive model    2.17   0.52--9.14    0.00    0.92      7              /
                             recessive         2.17   0.52--9.14            0.92      7              /
                             allele model      1.87   0.45--7.74    0.00    0.80      7              /
  Caucasian                  dominant model    1.45   1.28--1.64    37.90   0.04      23             /
                             additive model    1.72   1.00--2.96    0.00    1.00      23             /
                             recessive         1.74   1.01--2.99    0.00    1.00      23             /
                             allele model      1.43   1.26--1.62    42.50   0.02      22             /
  Others                     dominant model    0.99   0.46--2.10    0.00    0.46      3              /
                             additive model    0.98   0.10--9.61    0.00    1.00      3              /
                             recessive         2.17   0.22--21.12   0.00    0.57      3              /
                             allele model      1.14   0.78--1.66    0.00    0.64      4              /
  TLR4 299 vs UC                                                                                     
  Asian                      dominant model    1.86   0.46--7.46    0.00    1.00      8              /
                             additive model    1.86   0.46--7.46    0.00    1.00      8              /
                             recessive         1.86   0.46--7.46    0.00    1.00      8              /
                             allele model      1.86   0.46--7.46    0.00    1.00      8              /
  Caucasian                  dominant model    1.51   1.01--2.07    67.90   0.00      15             0.93
                             additive model    2.14   1.04--4.39    0.00    0.98      15             0.86
                             recessive         1.99   0.97--4.08    0.00    0.99      15             0.82
                             allele model      1.48   1.11--1.96    64.10   0.00      15             0.94
  Others                     dominant model    1.73   1.04--2.88    0.00    0.55      3              /
                             additive model    8.10   1.17--55.93   0.80    0.37      3              /
                             recessive         7.74   1.12--53.40   4.90    0.35      3              /
                             allele model      1.20   0.88--1.64    47.60   0.13      4              /
  TLR4 399 vs CD                                                                                     
  Asian                      dominant model    3.54   0.71--17.71   0.00    1.00      6              /
                             additive model    3.54   0.71--17.71   0.00    1.00      6              /
                             recessive         3.54   0.71--17.71   0.00    1.00      6              /
                             allele model      3.57   0.72--17.75   0.00    1.00      6              /
  Caucasian                  dominant model    1.20   0.97--1.49    0.00    0.78      8              /
                             additive model    0.98   0.30--3.21    0.00    0.78      8              /
                             recessive         0.96   0.29--3.14    0.00    0.78      8              /
                             allele model      1.19   0.96--1.46    0.00    0.62      8              /
  Others                     dominant model    1.58   0.85--2.93    0.00    0.91      2              /
                             additive model    1.28   0.32--5.11    0.00    0.87      2              /
                             recessive         1.07   0.28--4.16    0.00    0.92      2              /
                             allele model      1.20   0.85--1.69    0.00    0.70      3              /
  TLR4 399 vs UC                                                                                     
  Asian                      dominant model    1.93   0.39--9.59    0.00    1.00      6              /
                             additive model    1.93   0.39--9.59    0.00    1.00      6              /
                             recessive         1.93   0.39--9.59    0.00    1.00      6              /
                             allele model      1.93   0.39--9.59    0.00    1.00      7              /
  Caucasian                  dominant model    1.42   1.09--1.85    43.70   0.11      6              /
                             additive model    1.80   0.47--6.92    0.00    0.85      6              /
                             recessive         1.71   0.44--6.59    0.00    0.84      6              /
                             allele model      1.42   1.11--1.83    38.10   0.15      6              /
  Others                     allele model      0.91   0.62--1.35    0.00    0.67      2              /

TLR2 Arg677Trp {#sec015}
--------------

All studies evaluating the TLR2 Arg677Trp polymorphism were conducted among Asians. No variant allele A carrier or mutant homozygous was found in either the IBD patients or control population in the included studies. In addition, TLR2 Arg677Trp polymorphism did not show any association with CD (OR = 3.54, 95%CI = 0.71--17.71, P = 0.99) or UC (OR = 1.93, 95%CI = 0.39--9.60, P = 1.00) in Asian populations.

TLR2 Arg753Gln {#sec016}
--------------

Due to the rarity of the TLR2 Arg753Gln mutant homozygous genotype in the included studies, the data could only be pooled in the allele and dominant models. In the allele model, no association was found between the A allele and CD(A vs G: OR = 2.69, 95%CI = 0.77--9.44, P = 1.00)or UC(A vs G: OR = 1.81, 95%CI = 0.45--7.26, P = 1.00)susceptibility. Similarly, the AA genotype was not associated with risk of CD (AA vs GG: OR = 0.84, 95%CI = 0.53--1.82, P = 1.00) or UC (AA vs GG: OR = 1.14, 95%CI = 0.63--2.05, P = 1.00).

Subgroup analyses based on ethnic were performed to assess CD and UC susceptibility in Asians and Caucasians. No significant association was identified in both Asians(for CD, A vs G: OR = 3.54, 95%CI = 0.71--17.71, P = 0.99; AA vs GG: OR = 3.54, 95%CI = 0.71--17.71, P = 0.99; for UC, A vs G: OR = 1.93, 95%CI = 0.39--9.59, P = 1.00; AA vs GG: OR = 1.93, 95%CI = 0.39--9.59, P = 1.00) and Caucasians (G vs. A: OR = 1.05, 95% CI: 0.07--16.82, P = 0.99; AA vs. GG: OR = 0.73, 95% CI: 0.36--1.47, P = 0.48).

TLR4 Asp299Gly {#sec017}
--------------

A significantly increased susceptibility was found between TLR4 D299G and CD in the allele model (A vs G: OR = 1.40, 95%CI = 1.24--1.57, P = 0.1), dominant model (AA+GA vs GG: OR = 1.44, 95%CI = 1.27--1.63, P = 0.15), recessive model (AA vs GA+GG: OR = 1.82, 95%CI = 1.11--3.01, P = 1.00) and additive model (AA vs GG: OR = 1.62, 95%CI = 0.98--2.67, P = 1). Similar results were also found between TLR4 D299G and UC in the allele model (A vs G: OR = 1.40, 95%CI = 1.22--1.62, P = 0.01), dominant model (AA+GA vs GG: OR = 1.50, 95%CI = 1.28--1.76, P = 0.01), recessive model (AA vs GA+GG: OR = 2.25, 95%CI = 1.22--4.12, P = 1.00) and additive model (AA vs GG: OR = 2.37, 95%CI = 1.29--4.35, P = 1.00).

Stratified analyses by study quality and ethnicity were conducted to further explore the actual effect of TLR4 D299G polymorphism on the risk of CD and UC. Similar results were obtained with subgroup analyses by study quality. When ethnicity was restricted to Asians, no TLR4 D299G polymorphism was found in patients with CD or UC. However, when only studies with Caucasians were considered, a significant association with CD was obtained in all contrast models (A vs G: OR = 1.43, 95%CI = 1.26--1.62, P = 0.02; AA vs GG: OR = 1.72, 95%CI = 1.00--2.99, P = 1; AA+GA vs GG: OR = 1.45, 95%CI = 1.28--1.64, P = 0.04; AA vs GA+GG: OR = 1.74, 95%CI = 1.01--2.99, P = 1.00). Furthermore, significant associations with UC were found in the allele model (A vs G: OR = 1.48, 95%CI = 1.11--1.96, P\<0.01), dominant model (AA+GA vs GG: OR = 1.51, 95%CI = 1.10--2.07, P = P\<0.01) and additive model (AA vs GG: OR = 2.14, 95%CI = 1.04--4.39, P = 0.98). However, in the recessive model, only a marginal association (AA vs GA+GG: OR = 1.99, 95%CI = 0.97--4.08, P = 0.99) was found. Similar results were found in UC in Caucasians (A vs G: OR = 1.48, 95%CI = 1.11--1.96, P\<0.01; AA vs GG: OR = 2.14, 95%CI = 1.04--4.39, P = 0.98; AA+GA vs GG: OR = 1.51, 95%CI = 1.10--2.07, P\<0.01; AA vs GA+GG: OR = 1.99, 95%CI = 0.97--4.08, P = 0.99).

TLR4 Thr399Ile {#sec018}
--------------

The pooled results of all studies suggested that TLR4 T399I polymorphism was significantly associated with CD susceptibility in the dominant (TT+CT vs CC: OR = 1.26, 95%CI = 1.03--1.54, P = 0.97) and allele (T vs C: OR = 1.21, 95%CI = 1.01--1.44, P = 0.95) models, whereas no significant association was found in the recessive (TT vs CT+CC: OR = 1.35, 95%CI = 0.62--2.95, P = 0.98) and additive (TT vs CC: OR = 1.45, 95%CI = 0.66--3.18, P = 0.98) models. Similarly, the CC genotype significantly increased UC susceptibility in the dominant model (TT+CT vs CC: OR = 1.41, 95%CI = 1.09--1.82, P = 0.61) and the C allele was found associated with a higher UC susceptibility in the allele model (T vs C: OR = 1.26, 95%CI = 1.02--1.56, P = 0.52); no significant association was found in the recessive (TT vs CT+CC: OR = 1.84, 95%CI = 0.68--5.00, P = 1.00) and additive (TT vs CC: OR = 1.89, 95%CI = 0.70--5.13, P = 1.00) models.

Meta-analyses of high quality studies showed that TLR4 T399I polymorphism was not associated with the risk of CD in any genetic model and only the dominant model showed a significant association with the risk of UC.

Stratified by ethnicity, neither Asians nor Caucasians were associated with CD susceptibility in all four genetic models. With respect to UC, a significant association was found for Caucasians in dominant (TT+CT vs CC: OR = 1.42, 95%CI = 1.09--1.85, P = 0.11) and allele (T vs C: OR = 1.42, 95%CI = 1.11--1.83, P = 0.15) models, but not in recessive (TT vs CT+CC: OR = 1.71, 95%CI = 0.44--6.59, P = 0.84) and additive (TT vs CC: OR = 1.80, 95%CI = 0.47--6.92, P = 0.85) models.

Heterogeneity analysis {#sec019}
----------------------

For the TLR4 299 polymorphism versus UC, a statistically significant heterogeneity among studies was found in the dominant and allele models with the I^2^ values of heterogeneity\> and P values\< 0.10. To further investigate the heterogeneity in studies assessing TLR4 299 polymorphism in Caucasians, Galbraith plots were generated to identify the outliers which might contribute to this observation. Our results showed that the study published in 2008 by Rigoli was an outlier in both dominant and allele models ([Fig 3](#pone.0126803.g003){ref-type="fig"}). All I^2^ and P values decreased overtly after excluding 2008 Rigoli in dominant and allele models with Caucasians. The heterogeneity of the remainingmeta-analyses was acceptable.

![Galbraith plot of the association between TLR4 299 polymorphism and UC risk in Caucasians.\
Each figure represents a unique article in this meta-analysis. The figures outside the three lines were spotted as the outlier and the possible source of heterogeneity in the analysis pooled from the total available numbers. (a) Galbraith plot results of TLR4 299 polymorphisms and UC risk in the dominant model; (b) Galbraith plot results of TLR4 299 polymorphisms and UC risk in the allele model.](pone.0126803.g003){#pone.0126803.g003}

Sensitivity analysis {#sec020}
--------------------

Sensitivity analysis was performed by sequentially excluding individual studies. For analyses pooling more than three individual studies, the summary ORs were not influenced by excluding any single study (data not shown), indicating that our results were statistically robust.

Publication bias {#sec021}
----------------

There was no evidence of obvious asymmetry in the funnel plots. The Egger's test was performed to access publication bias in the articles included in this meta-analysis, when the number of included studies was greater than 10. All p values obtained in the Egger's test were more than 0.1 except for the dominant model of TLR4 399 in CD for both overall analysis and the assessment including only high quality studies. There were five unreported studies according to the Duval's trim and full method ([Fig 4](#pone.0126803.g004){ref-type="fig"}). After possibly unpublished studies were imputed, the pooled OR and 95%CI were slightly shifted toward null (Overall study: OR = 1.24, 95%CI = 1.02--1.51; High quality study: OR = 1.13, 95%CI = 0.91--1.42). However, no change was observed in the meta-analysis results.

![Funnel plots for studies evaluating TLR4 399 polymorphisms and risk of CD included in the meta-analysis.\
(a) Trim and fill data for all studies on TLR4 299 polymorphisms and UC risk in the dominant model; (b) Trim and fill data for high quality studies on TLR4 299 polymorphisms and UC risk in the dominant model. Imputed data (squares) are imaginary values to compensate for non-symmetric funnel plot.](pone.0126803.g004){#pone.0126803.g004}

Discussion {#sec022}
==========

Genome-wide association studies(GWAS) has improved our knowledge of many common variants and molecular pathways leading to IBD\[[@pone.0126803.ref059]\]. Recently, a meta-analyses of GWAS conducted by Jostins et al. have identified 163 loci that are significantly associated with IBD\[[@pone.0126803.ref060]\]. Such discoveries are limited to studies in North America, Oceania and Europe. Yang, S.K., et al. conducted a GWAS and two validation studies in the Korean population and revealed three new susceptibility loci for CD\[[@pone.0126803.ref061]\]. Till now, most GWAS were conducted in Caucasians with limited studies in other populations. Despite the success of GWAS in identifying IBD susceptibility loci, it explains only a minority of(\<25%) the variance in IBD risk\[[@pone.0126803.ref062]\]-. The advent of GWAS also prompt mechanistic research aimed at exploring the complex interplay between genes, immune networks, and microbiome. Functional studies to assess the in vivo impact of the genetic variants involved in IBD also emerges. Recently, Coelho, T et al. performed a unique systematic review of literature with mechanistic studies in assessing the functional impact of the a selected panel of gene variants implicated in IBD through GWAS and other genetic studies. However, they limited to only 71 genes and TLR is not included in the study. They did not make a meta-analysis due to the lack of functional studies and more functional studies is needed\[[@pone.0126803.ref063]\].

Both TLR4 and TLR2 was not detected to be associated with IBD in the previous GWAS. Not surprisingly, uncommon genetic variation which may contribute significantly toward the heritability of IBD may not be captured by GWAS\[[@pone.0126803.ref064]\]. Population-based studies have also provided compelling evidence for genetic factors contribute to the IBD for these rarer variants are more likely to be population specific. We performed a meta-analysis of population based case-control studis for TLR2 and TLR4 polymorphism and IBD susceptibility.

All studies assessing the TLR2 Arg677Trp polymorphism and IBD were carried out in Asia, and no TLR2 Arg677Trp polymorphism was found in Asians, as described above. This is the first meta-analysis evaluating TLR2 Arg677Trp polymorphism and IBD.

In the case of TLR2 Arg753Gln, we only pooled data in the allele and dominant models due to the rarity of the TLR2 Arg753Gln mutant homozygous genotype in the included studies. All studies were of high quality. Our meta-analysis showed no association between the Arg753Gln polymorphism and UC or CD. We then restricted to ethnicity-specific data for subgroup analyses, and found that the Arg753Gln polymorphism was not associated with UC or CD susceptibility in Asians or Caucasians. These findings indicated that Arg753Gln with the mutant allele does not significantly increase IBD susceptibility.To our knowledge, this is the first meta-analysis evaluating TLR2 Arg753Gln polymorphism and IBD.

Interestingly, this meta-analysis revealed a modest association between the TLR4 Asp299Gly polymorphism and IBD (CD and UC). This result was very well supported: sensitivity analyses excluding low quality studies did not significantly change the magnitude of the gene effect or genetic model. Next, we restricted to race-specific assessments to perform a subgroup analysis. Consistent with meta-studies reported by Hume and Shen\[[@pone.0126803.ref044], [@pone.0126803.ref052]\], our study suggested that TLR4 Asp299Gly polymorphism might be associated with UC and CD susceptibility in Caucasians. Browning et al found no relationship between TLR4 Asp299Gly and UC in Caucasians, which contradicts our findings\[[@pone.0126803.ref042]\]. However, only 12 articles were included in their study. Some differences exist between our study and Hume and Shen's reports. First, the included studies were updated. Then, quality assessment and publication bias assessment of the included studies were performed. TLR4 Asp299Gly polymorphism was not associated with UC or CD in Asians in our study. Ng et al. has made a systematic review and meta-analysis of genetics of IBD in Asia and they also found no association of TLR4 Asp299Gly and risk of CD\[[@pone.0126803.ref065]\].However, they only included two studies (Xiong 2006 and Ye 2009) conducted in Chinese and Korean patients. We included 7 more studies with 1 conducted in Japanese, 1 in Korean and 5 in Chinese. Our study might further confirm that population differences, such as genetic heterogeneity, play a vital role in IBD susceptibility.

The current study indicates that the TLR4 399T allele might increase the risk of UC and CD. It is plausible that TLR4 Thr399Ile's T allele affect TLR4 transcription and expression, further impacting TLR4 protein function. Further studies should focus on how the variant might impact gene expression and function. Subgroup analysis of high quality studies showed no association between TLR4 Thr 399Ile polymorphism and CD, and marginal association between TLR4 Thr399Ile polymorphism and UC. In the meta-analysis performed by Shen et al\[[@pone.0126803.ref052]\], TLR4 399 Ile polymorphism is associated with both UC and CD susceptibility in Caucasians. Our race-specific subgroup analyses found that the TLR4 Thr 399Ile polymorphism was associated with UC susceptibility in Caucasians while no association between TLR4 Thr399Ile polymorphism and CD susceptibility was observed. For Asians, there was no association observed in any genetic model for TLR4 Thr399Ile and CD or UC susceptibility.

The overall meta-analysis has little heterogeneity. When ethnicity sub-stratification was performed, heterogeneity was decreased or even removed among Asians while significant heterogeneity existed in study for TLR4 Asp299Gly polymorphism and UC in the dominant and allele models in Caucasions. Galbraith plot was used to identify heterogeneous records. One heterogeneous article for TLR Asp299Gly vs UC was detected by the Galbraith plot\[[@pone.0126803.ref043]\]. The potential bias of the article might result from the elderly population assessed or unknown reasons. After omitting this article, heterogeneity decreased substantially and the association was still significant. The Egger's test suggested that there was no significant publication bias except for the meta-analysis of TLR4 Thr399Ile and CD in the dominant model. This publication bias was then corrected using the Duval's trim and fill method. Publication bias is caused by the tendency of researchers and editors to publish reports with positive results, while those showing inconclusive results are likely not considered for publication. Several original studies has controls depart from the HWE which may cause bias in estimates of genetic effects results. Currently, there is no consensus on whether to pool studies that are not in HWE for meta-analysis of genetic association studies. We performed a quality assessment of the studies based on the HWE as well as other criteria such as representativeness of cases and controls. Sensitive analysis quality were also performed by excluding low quality studies in our study which is the merit of our study.

A few limitations of this study need to be mentioned. First, a variety of confounding factors may be associated with increased damage to IBD, such as gender, age, smoking status, clinical phenotype, et al. Unfortunately, we were unable to obtain sufficient data to perform appropriate stratified analyses due to the limited information in the included studies. In addition, the number of cases and controls included was relatively small and most were included in Asians as far as studies on TLR2 Arg677Trp and Arg753Gln are concerned. Thus, the association between in different populations need to be confirmed by further studies. Finally, we could not identify the gene-gene and gene-environment interactions in this study. In conclusion, TLR2 Arg677Trp and Arg753Gln is not associated with the risk of UC or CD. The TLR4 Asp299Gly and Thr399Thr genotypes seem to be more susceptible to UC and CD in Caucasian populations but not in Asians. This finding needs to be further confirmed in future well-designed studies including different ethnicities.
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